POINT Biopharma USA Inc. – FDA Inspection, Jun 7, 2024

Record Details

This FDA Inspection record concerns POINT Biopharma USA Inc., with an inspection on June 7, 2024, issued by the Detroit District Office, covering human drugs.

Company: POINT Biopharma USA Inc.
Inspection Date: June 7, 2024
Product Type: Human Drugs
Office: Detroit District Office
People: Matthew M. Schuckmann (Issuing Officer)
Muna Algharibeh (FDA Associated Person)

View Company Profile

ID · efc7aa6b-4ef1-40c9-a20c-e4006bec2eb0

Inspection Facts

Inspection number: 1240823
FDA center: Human Drugs
Outcome: Form 483 issued

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore POINT Biopharma USA Inc.

FDA Inspection

POINT Biopharma USA Inc.June 7, 2024

POINT Biopharma USA Inc. – FDA Inspection, Jun 7, 2024

Record Details

This FDA Inspection record concerns POINT Biopharma USA Inc., with an inspection on June 7, 2024, issued by the Detroit District Office, covering human drugs.